tirzepatide shortage fda update confirms is still over, gives compounders a grace period Eli Lilly joins FDA as

Patients with a history of severe gastrointestinal disease, particularly those with inflammatory bowel disease, severe gastroesophageal reflux disease, or history of pancreatitis, require careful evaluation before considering this therapy

The upcoming SURMOUNT-MAINTAIN trial, expected to report results around mid-2026, will specifically compare the 5 mg maintenance dose against higher doses for weight maintenance after initial loss

Those at high risk may need a glucagon prescription

Others dread injection day

This financial reality is why compounded options have gained so much traction

A 0.3 mL syringe with half-unit markings can measure 18.5 or 19 units with reasonable precision